Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Drucker

Showing results (71-80 of 313) with videos related to

Pageof 32
Sort By:
Endocrine Pathology|May 7, 2020
Transgenic mice in the study of endocrine systemsRobert V Campos, Daniel J Drucker
Diabetes|April 29, 2006
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cellsJacqueline A Koehler, Daniel J Drucker
Endocrinology|December 17, 2004
Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosaJennifer L Estall, Daniel J Drucker
Lancet (London, England)|February 15, 2011
Cardiovascular safety and diabetes drug developmentDaniel J Drucker, Allison B Goldfine
Endocrine Reviews|September 13, 2014
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitorsErin E Mulvihill, Daniel J Drucker
Gastroenterology|May 15, 2007
Biology of incretins: GLP-1 and GIPLaurie L Baggio, Daniel J Drucker
Lancet (London, England)|November 14, 2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesDaniel J Drucker, Michael A Nauck
The Journal of Clinical Investigation|September 10, 2014
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weightLaurie L Baggio, Daniel J Drucker
Endocrine Reviews|July 30, 2022
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver DiseaseJulian M Yabut, Daniel J Drucker
Diabetes|June 16, 2025
Therapeutic Targeting of the GIP Receptor-Revisiting the ControversiesJonathan E Campbell, Daniel J Drucker
Pageof 32

Showing results (71-80 of 313) with videos related to

Sort By:
Pageof 32
Endocrine Pathology|May 7, 2020
Transgenic mice in the study of endocrine systemsRobert V Campos, Daniel J Drucker
Diabetes|April 29, 2006
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cellsJacqueline A Koehler, Daniel J Drucker
Endocrinology|December 17, 2004
Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosaJennifer L Estall, Daniel J Drucker
Lancet (London, England)|February 15, 2011
Cardiovascular safety and diabetes drug developmentDaniel J Drucker, Allison B Goldfine
Endocrine Reviews|September 13, 2014
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitorsErin E Mulvihill, Daniel J Drucker
Gastroenterology|May 15, 2007
Biology of incretins: GLP-1 and GIPLaurie L Baggio, Daniel J Drucker
Lancet (London, England)|November 14, 2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesDaniel J Drucker, Michael A Nauck
The Journal of Clinical Investigation|September 10, 2014
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weightLaurie L Baggio, Daniel J Drucker
Endocrine Reviews|July 30, 2022
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver DiseaseJulian M Yabut, Daniel J Drucker
Diabetes|June 16, 2025
Therapeutic Targeting of the GIP Receptor-Revisiting the ControversiesJonathan E Campbell, Daniel J Drucker
Pageof 32